Committed to developing novel vaccines against major infectious diseases and public health threats worldwide
Patronus Biotech, a subsidiary of Luye Life Sciences, is the first vaccine company in China to focus on the Universal Virus Like Particles (U-VLP™) technology. Its independently built U-VLP ™ platform has broken through the limitations of traditional VLP technology on pathogen types, as well as technological bottlenecks in production capacity and stability. Multiple invention patents have been authorized. Patronus has currently built pilot and commercial manufacturing sites that meet international standards, with an annual production capacity of up to 1 billion doses. Based on U-VLP ™ platform,Patronus has laid out pipelines that urgently needed in clinical practice, some of which have entered the clinical stage, hoping to providing safer and more efficient solutions for the prevention and control of major epidemics and infectious diseases.
Unique U-VLP™ (Universal Virus-Like Particles) platform
Breaks through the limitations of traditional VLP technology in pathogen types
Stable and high yield:
Breaks bottlenecks of traditional VLP manufacturing technology
Broad spectrum:
Can be used for rapid development of a wide range of pathogenic vaccines, including emergency products such as COVID vaccine
Stronger efficacy:
Particle presentation improves the immunogenicity of otherwise poorly immunogenic protein antigens, together with steric presentation promotes conserved epitopes recognition thus higher broadly neutralising antibody titers
Pilot workshop
Manufacture workshop